PureTech Health News
Press Releases
Press releases 2017-11-20
Selective mTORC1 Inhibitors
PureTech’s resTORbio Advances Immunotherapy Candidate for Aging-Related Conditions Following Recommendation from Independent Data Monitoring Committee

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, announced today that resTORbio, Inc., an affiliate of PureTech Health, has begun dosing patients in the second part of a Phase 2b clinical study designed to assess the safety, tolerability and efficacy of resTORbio’s lead programme in reducing respiratory tract infections (RTIs) in the elderly.

Continue
Press releases 2017-11-09
PureTech Health to Present at Jefferies 2017 Healthcare Conference in London

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced that Eric Elenko, PhD, Chief of Research and Strategy at PureTech Health, will present at the Jefferies 2017 Global Healthcare Conference in London on Thursday, 16 November, at 8.00AM GMT. 

Continue
Press releases 2017-11-03
Microbiome-Derived Immune Modulators
PureTech’s Vedanta Biosciences Awarded $5.4 Million Grant from Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to Support Development of a Novel Human Microbiome-Derived Treatment

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, today announced that it has been awarded a $5.4 million research grant from CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator) to support clinical testing of its lead oral product candidate, VE303, a novel human-microbiome drug candidate to address serious bacterial infections.

Continue
Press releases 2017-11-01
Microbiome-Derived Immune Modulators
PureTech Health’s Vedanta Licenses Microbiome-Derived Immuno-Oncology Product Candidates

PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Vedanta Biosciences, an affiliate of PureTech Health, has exclusively sub-licensed key intellectual property to develop and commercialize microbiome-derived cancer immunotherapies based on live biotherapeutics.

Continue
Press releases 2017-09-25
PureTech Health’s Gelesis Reports Significant Weight Loss with Excellent Safety Profile in Pivotal Study with Gelesis100

PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that Gelesis, an affiliate of PureTech Health, today announced topline results from the pivotal weight loss study (GLOW) of one of its product candidates, Gelesis100.

Continue
Press releases 2017-09-20
Vocal Biomarkers
PureTech Health Notes US Patent Issuance Broadly Covering Methods of Assessing Mental and Physical Condition from Human Speech
PureTech Health plc (“PureTech Health” or the “Company”, LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,763,617 for its Sonde vocal biomarkers programme.
Continue
Press releases 2017-09-19
PureTech Health Exclusively Licenses Novel Milk-Derived Exosome Technology for Oral Administration of Biologics, Nucleic Acids, and Complex Small Molecules

PureTech Health plc (“PureTech Health” or the “Company”, LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced an exclusive licensing agreement with 3P Biotechnologies, Inc., via University of Louisville, for an exosome-based technology (Calix) for the oral administration of biologics, nucleic acids, and complex small molecules.

Continue
Press releases 2017-08-29
Lymphatic Targeting
PureTech Health Exclusively Licenses Glyph Technology from Monash University to Harness Lymphatic Biology

Novel approach designed to enable oral administration of medicines that traffic via the lymphatic system and selectively target the lymph nodes.

Full article

Press releases 2017-08-15
PureTech Health Notice of Half-Yearly Results
Press releases 2017-07-13
PureTech Health Presents Data Supporting Treatment Approach for Interstitial Cystitis/Bladder Pain Syndrome Based on Novel Alivio Inflammation-Targeting Technology

@PureTechH

Exploring the Brain Immune Gut Interface

Targeting serious diseases caused by dysfunctions in the brain-immune-gut axis

See Our Science